UK Patents Act Allows Researchers to Use Patented Drugs in Trials
A recent news confirmed about changes in the UK Patents Act, according to which patented drugs would be allowed to use for medical trails. It has been announced by the Department for Business, Innovation and Skills (BIS), thereby giving a sense of relief to researchers about patent infringement risk.
It is believed that the ruling would play crucial role in conducting studies to support health technology assessment (HTA), which is imperative to make a product cost effective before approval. The decision has appreciated by the industry as Stephen Whitehead, chief executive of trade body the Association of the British Pharmaceutical Industry (ABPI), said: "This is a welcome development that will make the UK a more attractive place in which to conduct clinical trials, which in turn will encourage pharmaceutical companies to continue operating here".
Moreover, it has been welcomed by the UK biotech trade body, the BioIndustry Association (BIA) as it would strengthen the stance of UK research amid fierce competition from developing countries including India and China. It is to be noted that the BIA had proposed the same during their consultation, which ran for eight weeks from October 24.
It is hoped that this move would be able to take the pharmaceutical research and development in the UK to another level.
New Zealand News
- German automaker Volkswagen invests $620 million in Northvolt to secure EV battery supply
- Top places to see in Singapore
- Xpeng enjoys 483% year-over-year jump in May 2021 deliveries; thanks to robust sale of P7
- Tesla offering new discounts & perks in China amid negative press
- Electric Vehicle Council slams Victoria Government for proposed punitive mileage tax on electric cars